Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LSS | P48449 | 1/20 | 1.00 |
| ▸ | DNM1 | Q05193 | 10/20 | 0.60 |
| ▸ | HTT | P42858 | 2/20 | 0.60 |
| ▸ | SLC22A1 | O15245 | 1/20 | 0.58 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.55 |
| ▸ | TP53 | P04637 | 1/20 | 0.55 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.55 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.55 |
| ▸ | TSHR | P16473 | 1/20 | 0.55 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.55 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.55 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.55 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL80039 | 1.00 | LSS (1.00) | LSSDNM1HTTSLC22A1ALDH1A1 | |
| SCHEMBL10935770 | 1.00 | LSS (1.00) | LSSDNM1HTTSLC22A1ALDH1A1 | |
| SCHEMBL27363 | 1.00 | LSS (1.00) | LSSDNM1HTTSLC22A1ALDH1A1 | |
| SCHEMBL2079306 | 1.00 | LSS (1.00) | LSSDNM1HTTSLC22A1ALDH1A1 | |
| SCHEMBL1964346 | 1.00 | LSS (1.00) | LSSDNM1HTTSLC22A1ALDH1A1 | |
| SCHEMBL6699768 | 1.00 | LSS (1.00) | LSSDNM1HTTSLC22A1ALDH1A1 | |
| SCHEMBL10935932 | 1.00 | LSS (1.00) | LSSDNM1HTTSLC22A1ALDH1A1 | |
| SCHEMBL6684716 | 1.00 | LSS (1.00) | LSSDNM1HTTSLC22A1ALDH1A1 | |
| SCHEMBL8429676 | 1.00 | LSS (1.00) | LSSDNM1HTTSLC22A1ALDH1A1 | |
| SCHEMBL10935037 | 1.00 | LSS (1.00) | LSSDNM1HTTSLC22A1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1069 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12597611-B2 | Cathode for an electrochemical cell including at least one cathode additive | DURACELL U.S. OPERATIONS, INC. (US) | 2026-04-07 | — | — | US | claimed |
| WO-2023087195-A1 | FAST DRYING MULTI-PURPOSE CLEANING AND DISINFECTING COMPOSITIONS AND METHODS OF THEIR USE | ECOLAB USA INC. (US) | 2023-05-25 | — | — | WO | claimed |
| EP-3909428-A1 | ENHANCED PRESERVATIVE | Arch Chemicals, Inc. (US) | 2021-11-17 | — | — | EP | claimed |
| US-11075382-B2 | Cathode for an electrochemical cell including at least one cathode additive | DURACELL U.S. OPERATIONS, INC. (US) | 2021-07-27 | — | — | US | claimed |
| EP-3149794-A1 | CATHODE FOR AN ELECTROCHEMICAL CELL INCLUDING AT LEAST ONE CATHODE ADDITIVE | Duracell U.S. Operations, Inc. (US) | 2017-04-05 | — | — | EP | claimed |
| US-9287052-B2 | Additives for dye-sensitized solar cells | MERCK PATENT GMBH (DE) | 2016-03-15 | — | — | US | claimed |
| US-20150349344-A1 | CATHODE FOR AN ELECTROCHEMICAL CELL INCLUDING AT LEAST ONE CATHODE ADDITIVE | DURACELL U.S. OPERATIONS, INC. | 2015-12-03 | — | — | US | claimed |
| US-20130292601-A1 | Additives for Dye-Sensitized Solar Cells | MERCK PATENT GMBH (DE) | 2013-11-07 | — | — | US | claimed |
| CN-101687789-A | Novel inhibitors hepatitis c virus replication | INTERMUNE INC | 2010-03-31 | — | — | CN | claimed |
| EP-2134683-A2 | NOVEL INHIBITORS HEPATITIS C VIRUS REPLICATION | Intermune, Inc. (US) | 2009-12-23 | — | — | EP | claimed |
| US-20090047246-A1 | NOVEL INHIBITORS OF HEPATITIS C VIRUS REPLICATION | INTERMUNE, INC. (US) | 2009-02-19 | — | — | US | claimed |
| WO-2008100867-A2 | NOVEL INHIBITORS HEPATITIS C VIRUS REPLICATION | INTERMUNE, INC. (US) | 2008-08-21 | — | — | WO | claimed |
| US-20030134420-A1 | Methods and compositions for gene delivery | IMMUNE RESPONSE CORPORATION, THE | 2003-07-17 | — | — | US | claimed |
| WO-2001060415-A1 | METHODS AND COMPOSITIONS FOR GENE DELIVERY | THE IMMUNE RESPONSE CORPORATION (US) | 2001-08-23 | — | — | WO | claimed |
| US-20260146216-A1 | MULTI-USE HEAVY-DUTY CLEANING AND DEGREASING COMPOSITION IN A SOLID DOSE | ECOLAB USA INC. (US) | 2026-05-28 | — | — | US | disclosed |
| EP-4227391-B1 | DETERGENT COMPOSITION THAT PERFORMS BOTH A CLEANING AND RINSING FUNCTION | ECOLAB USA INC (US) | 2026-05-27 | — | — | EP | disclosed |
| EP-3589777-B1 | ALKALINE CLEANING COMPOSITIONS COMPRISING AN ALKYLAMINO HYDROXY ACID AND/OR SECONDARY AMINE AND METHODS OF REDUCING METAL CORROSION | ECOLAB USA INC (US) | 2026-05-20 | — | — | EP | disclosed |
| EP-0764224-A1 | METHOD FOR IMPROVING CELLULOSE FIBER | Kao Corporation (JP) | 1997-03-26 | — | — | EP | disclosed |
| WO-1996031645-A1 | METHOD FOR IMPROVING CELLULOSE FIBER | KAO CORPORATION (JP) | 1996-10-10 | — | — | WO | disclosed |
| US-4747967-A | Use of amine oxide in the H2 O2 oxidation of aliphatic mercaptan to sulfonic acid | ETHYL CORPORATION (US) | 1988-05-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12597611-B2 | Cathode for an electrochemical cell including at least one cathode additive | EED, SELE, CTNND1 | LSS 2324/4885DNM1 1718/4885HTT 4099/4885 |
| US-20260146216-A1 | MULTI-USE HEAVY-DUTY CLEANING AND DEGREASING COMPOSITION IN A SOLID DOSE | C9, RAD23B, PRDX2 | LSS 4611/4885DNM1 3847/4885HTT 2927/4885 |
| US-20090047246-A1 | NOVEL INHIBITORS OF HEPATITIS C VIRUS REPLICATION | EIF2AK2, HAVCR2, HCCS | LSS 2639/4885DNM1 2422/4885HTT 4192/4885 |
| US-20030134420-A1 | Methods and compositions for gene delivery | POLRMT, NUP205, POLM | LSS 4419/4885DNM1 662/4885HTT 748/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.